4.2 Article

Role of monocyte chemoattractant protein-1, tumor necrosis factor-α and interleukin-6 in the control of malignant pleural effusion and survival in patients with primary lung adenocarcinoma

期刊

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
卷 27, 期 2, 页码 E118-E124

出版社

WICHTIG EDITORE
DOI: 10.5301/JBM.2012.9197

关键词

Interleukin-6; Lung adenocarcinoma; Malignant pleural effusion; Monocyte chemoattractant protein-1; Tumor necrosis factor-alpha; Survival

资金

  1. Great Medical Research Program of the Nanjing Sanitary Bureau of Jiangsu Province Personalized Therapy of Non Small Cell Lung Cancer Patients
  2. Jiangsu Province Natural Science Foundation of China [BK2008326]
  3. Medical Foundation for Distinguished Scholar in Jiangsu Province [RC2007113]

向作者/读者索取更多资源

This study aimed at assessing the role of monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in the control of pleural effusion (PE) and survival in patients with primary lung adenocarcinoma. The concentrations of the 3 cytokines were measured in PE from 79 lung adenocarcinoma patients with malignant pleural effusion (MPE) and 23 patients with tuberculosis. Data were correlated with the efficacy of MPE control and patient survival. The level of MCP-1 in PE was significantly higher in patients with lung adenocarcinoma than those with tuberculosis. By contrast, the levels of TNF-alpha and IL-6 were significantly lower in patients with lung adenocarcinoma than those with tuberculosis. An MCP-1 level greater than 3,187 pg/mL (which was used as a cutoff point) indicated failure to control MPE (odds ratio [OR]=2.82, 95% confidence interval [CI]=1.02-7.82, p=0.04). In multivariate analysis, MCP-1 was confirmed as an independent prognostic factor for progression-free survival (hazard ratio [HR]=2.02, 95% CI=1.24-3.30, p=0.01). The level of MCP-1 in PE appears to be a reliable surrogate marker for evaluating the therapeutic efficacy in the control of MPE and predicting survival in lung adenocarcinoma patients with MPE.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据